US Pharma MarketingEli Lilly wins argument over Noom’s GLP-1 dosing claims
Eli Lilly has successfully challenged Noom’s “A Smaller Dose. Eli Lilly has successfully challenged Noom’s “A Smaller Dose. A Smarter Start” claim, leading the National Advertising Division (NAD) to recommend the digital health company change or drop the statement.
Eli Lilly has successfully challenged Noom’s “A Smaller Dose. A Smarter Start” claim, leading the National Advertising Division (NAD) to recommend the digital health company change or drop the statement.
Source: FiercePharma